Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.

Abstract

Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient\u27s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies